Iqvia Holdings Inc (NY: IQV )
215.56 USD +1.43 (+0.67%) Official Closing Price Updated: 6:59 PM EDT, Apr 16, 2021 Add to My Watchlist
Press releases about Iqvia Holdings Inc
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) will announce its first-quarter 2021 financial results before the market opens on Thursday, April 22, 2021. The IQVIA management team will also host a...
Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses,...
From PR Newswire
Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced the sale of its minority share in Q2 Solutions to IQVIA (NYSE: IQV), a leading global...
From PR Newswire
IQVIA Acquires Remaining Interest in Q2 Solutions from Quest Diagnostics; Raises Full Year 2021 Adjusted Diluted EPS Guidance
April 01, 2021
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, today announced the...
IQVIA Virtual Trial Solutions Used in More than 60 Trials
March 09, 2021
IQVIA™ (NYSE:IQV) announced today that more than 60 trials spanning over 40 countries utilize its innovative decentralized clinical trial solutions as part of their respective registration trials. Many...
IQVIA Collaborating with Janssen Research & Development on Their Investigational COVID-19 Vaccine Trials
March 08, 2021
IQVIA™ (NYSE: IQV) announces that since September 2020 it has been collaborating with Janssen Research & Development, LLC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, on the Phase...
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), announced today that Ron Bruehlman, executive vice president and chief financial officer, will participate in a virtual fireside chat at the Barclays Global...
IQVIA Announces Pricing of Offering of Senior Notes
February 17, 2021
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) today announced that its wholly owned subsidiary, IQVIA Inc. (the “Issuer”), priced an offering of €1,450,000,000 in aggregate principal amount of senior notes,...
AIS Announces Patricia Obermaier Microsoft VP of U.S. Health and Life Sciences Joins Board of Directors
February 16, 2021
AIS announced today the addition of Patricia Obermaier, Microsoft VP of U.S. Health and Life Sciences, to its Board of Directors.
IQVIA Announces Offering of Senior Notes
February 16, 2021
IQVIA’s Orchestrated Customer Engagement (OCE) Solution Selected by 140 Life Sciences Companies in Nearly 90 Countries
February 11, 2021
IQVIA™ (NYSE:IQV) today announced that 140 life science companies in nearly 90 countries have selected Orchestrated Customer Engagement (OCE) as their customer engagement solution. This milestone...
IQVIA Reports Fourth-Quarter and Full-Year 2020 Results Raises Full-Year 2021 Guidance
February 10, 2021
IQVIA Recognized as Leading eCOA/ePRO Provider in Latest 2020 ISR eCOA/ePRO Market Report
February 04, 2021
IQVIA™ (NYSE: IQV) today announced that it has been recognized as a top performer by survey respondents in Industry Standard Research’s eCOA/ePRO Market Dynamics and Service Provider Performance (4th...
IQVIA Named to FORTUNE’s 2021 List of “World’s Most Admired Companies”
February 01, 2021
IQVIA Holdings Inc. (“IQVIA”) (NYSE: IQV) has been named to FORTUNE magazine’s “World’s Most Admired Companies” list. IQVIA has received this distinction every year, following the merger between IMS...
Laboratoires Théa Selects IQVIA OCE and OneKey to Accelerate Its Global Digital Transformation
January 05, 2021
Laboratoires Théa selected IQVIA OCE platform and the OneKey HCP/HCO reference database for deployment across more than 22 markets.
Q2 Solutions, an IQVIA and Quest Diagnostics Joint Venture, Teams With Adaptive Biotechnologies to Market immunoSEQ® Assay, the Leading Quantitative Large-Scale Immunosequencing Solution
December 21, 2020
Q2 Solutions, a leading global clinical trial laboratory services organization, resulting from an IQVIA and Quest Diagnostics joint venture, today announced a partnership with Adaptive Biotechnologies,...
Prescription Opioid Use in the U.S. has Declined by 60% from 2011 Peak, According to New Report from the IQVIA™ Institute for Human Data Science
December 17, 2020
Another year of double-digit decline in prescription opioid use in 2020 is expected to reduce usage in the US to levels not seen since the early 2000s
IQVIA and Servier Collaborate to Reinvent Clinical Development
December 16, 2020
IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, today announced a collaboration with Servier, an...
IQVIA Supports Collaborative Forum of Top Pharma Leaders to Advance the Use and Acceptance of Real World Evidence
December 07, 2020
IQVIA™ (NYSE: IQV) said today that it is pleased to be a supporter of the Real World Evidence Leadership Forum, a group consisting of senior RWE executives from 18 major pharmaceutical companies. The...
Abivax Completes Recruitment of ABX464 Phase 2b Induction Study in Ulcerative Colitis
November 30, 2020
IQVIA’s Orchestrated Customer Engagement Platform Selected by Zentiva to Accelerate Digital Capabilities
November 02, 2020
IQVIA™, a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, today announced that Zentiva, a leading player in branded...
IQVIA Reports Third-Quarter 2020 Results, Raises Full-Year 2020 Guidance and Provides 2021 Outlook
October 20, 2020
IQVIA Joins FDA to Advance COVID-19 Understanding at Community Level through COVID Active Research Experience (CARE) Project
October 12, 2020
IQVIA™ (NYSE: IQV), in scientific partnership with the U.S. Food and Drug Administration, will provide agile analytics from IQVIA’s CARE Project COVID-19 registry to support better understanding of how...
IQVIA to Announce Third-Quarter Results on October 20, 2020
October 07, 2020
IQVIA Holdings Inc. (“IQVIA”) (NYSE: IQV), will announce its third-quarter financial results before the market opens on Tuesday, October 20, 2020. The IQVIA management team will also host a conference...
IQVIA Institute for Human Data Science Study: Biosimilars Reach Inflection Point – On Track to Reduce Drug Costs by $100 Bn Over Next Five Years
October 06, 2020
Biosimilar medicine availability and use are growing and on track to reduce drug costs by $100 billion over the next five years, according to a new report from the IQVIA Institute for Human Data...
IQVIA’s eCOA Solution Receives 2020 Fierce Innovation Award
September 14, 2020
IQVIA™ (NYSE: IQV) today announced that its electronic Clinical Outcome Assessment (eCOA) solution, an advanced-study build and execution platform that optimizes real-time, direct-from-patient data...
IQVIA’s RIM Smart Honored as Gold Stevie® Award Winner in 2020 American Business Awards®
August 31, 2020
IQVIA™ (NYSE: IQV) was recognized at the 18th Annual American Business Awards®, winning the Gold Stevie® Award for Technical Innovation of the Year. IQVIA also won a Silver Stevie Award for Most...
IQVIA™ (NYSE: IQV) today announced that Nancy Dreyer, chief scientific officer and senior vice president, Real World Solutions, has been awarded PharmaVOICE magazine’s Red Jacket honor after she was...
Drug Prices Have Become More Affordable to Most Patients, says U.S. Medicine Spending Study from the IQVIA Institute for Human Data Science
August 04, 2020
The vast majority of patients in the United States are experiencing lower out-of-pocket costs for their drugs, paying a smaller share of costs and seeing a downward trend in their costs on average....